Antibacterial Agents TRIZ Cases

Engineered anti-hLIGHT antibodies neutralize specific polymorphisms to block epithelial cell damage and reduce inflammatory responses in bowel diseases.

A meningococcal conjugate vaccine formulation limits unconjugated carrier protein concentration below 10 μg/ml to preserve immune response efficacy.

SHAAGtides recruit immune cells via FPRL1 binding, reducing vaccine administration barriers.

A ω-1H-imidazole-carboxamide polymer moiety conjugates indolocarbazole compounds through a 5-member oxazolidindionic cyclic structure.

Transgenic non-human mammals express human C1 inhibitor in milk, resolving low yield and contamination risks associated with plasma-derived sources.

Fatty acid conjugation stabilizes lipidated peptides against serum binding while maintaining broad-spectrum activity against resistant bacteria.

A process for stereoselective production of 3-acyloxyacrylonitrile compounds using alkali metal alkoxides in hydrocarbon solvents.

Eryngial treats infections caused by resistant trypanosomes and bacteria using parameter changes to overcome drug resistance.

Recombinant Cystatin C and 9 restrain systemic inflammation while preserving gut microbiome integrity.

Maltose reduces 4-epimer levels below 3% by controlling epimerization degradation pathways.

A combination vaccine device merges checkpoint antibodies with scaffold compositions to boost T cell activity.

Vitamin E succinate replaces toxic polysorbate 80 in docetaxel formulations, eliminating allergic reactions while maintaining solubility.

Inorganic nitrite reduces neuropathy tissue damage by modulating angiogenesis and inflammatory responses.

Short synthetic peptide sequence overcomes antibiotic resistance development while maintaining strong efficacy against bacterial and fungal pathogens.

A multi-valent cationic antiseptic oral care kit applies a compatible moisturizer to intubated patients.

Beta-functionalized chlorin photosensitizers absorb red and near-infrared light to enable deeper tissue penetration.

Dual CXCR1/CXCR2 inhibitors block neutrophil recruitment pathways.

Bioconjugate vaccines synthesized in Escherichia coli using N-linked glycosylation technology.

Specific Lactobacillus strains compete for intestinal adhesion sites, reducing Clostridium difficile infection severity and histological lesions.

Plasminogen activation degrades bacterial biofilms and stimulates cytokine expression to resolve antibiotic resistance in periodontal disease treatment.

Combining these agents with efflux pump inhibitors restores activity against resistant strains.

Segmented base and cover layers resolve wet handling trade-offs while maintaining in vivo degradability through localized hydrophobic protection.

Targeted compounds interfere with ATP synthase to treat multi-drug-resistant tuberculosis and latent infections.

A medicine composition using carbanions and a diluting agent to facilitate organ treatment in mammals.

Selective EP4 receptor antagonists inhibit IL-23 production, reducing inflammation without exacerbating colitis.

Immobilized phthalocyanine derivatives on polymers produce reactive oxygen species to inactivate microorganisms.

Pyrroloquinoline derivatives target DNA gyrase B to overcome multidrug resistance in tuberculosis and staphylococcal infections.

Polymyxin analogues incorporate heteroaryl groups at the N-terminus to maintain antibacterial efficacy against Gram-negative bacteria.

Fluorinated cyclic dinucleotides resist acid degradation to enhance mucosal immunity against gastrointestinal infections.

Cyclodextrin and pH-dependent ionizable anions stabilize mupirocin within liposomes, enabling systemic delivery despite rapid bloodstream degradation.

Bacteriophage ΦCJ21 treats necrotic enteritis in livestock without antibiotic resistance through specific biological lysis.

A hydroxamic acid derivative inhibits the LpxC enzyme to combat drug-resistant gram-negative bacteria.

Aminoquinolone compounds inhibit glycogen synthase kinase-3 activity, addressing insufficient therapeutic effectiveness of existing agents.

Effervescent amino acid salt compositions raise oral pH to inhibit demineralization and reduce dental caries without swallowing dry pills.

Replacing fermentable sugars with non-fermentable alternatives eliminates explosion risks from gas fermentation while maintaining electrolyte homeostasis.

Nucleic acid aptamers replace immunogenic antibodies by chemically modifying backbones to maintain binding affinity while reducing immune response.

Replacing sugar rings with cyclohexane derivatives reduces production costs while maintaining therapeutic efficacy for endothelial dysfunction.

Chimeric alpha helical and proline-rich domains of PspA induce broad immunity, resolving limited serotype coverage in current vaccines.

Ion exchange chromatography purifies heat shock protein-peptide complexes using a salt gradient elution mechanism.

Cell microvesicles transport functional microRNAs from the common bile duct to remote tissues for targeted gene regulation.

Novel bacteriophage composition targets Salmonella Enteritidis and Typhimurium through specific lysis without affecting beneficial microbiota.

Heat treatment reduces lipase activity in bacterins to prevent emulsion breakdown and preserve adjuvant effectiveness.

Substituted benzylideneguanidine derivatives reverse bacterial drug resistance and improve growth promotion in livestock.

Rabeximod reduces pro-inflammatory cytokines to alleviate acute respiratory distress while lowering healthcare resource consumption.

Mycobacterium tuberculosis-derived adenosine kinase binds lipopolysaccharide to inhibit cell interaction.